The National Institutes of Health, through its NIH Guide, has recently published the following funding-related notices and funding opportunities:

Policy Notices

• Upcoming Changes to the Federal Financial Report (FFR) Beginning April 1, 2022
  (NOT-OD-22-099)
  National Institutes of Health
  Agency for Healthcare Research and Quality

General Notices

• Pre-Application Webinar for NOT-CA-22-056, Administrative Supplements to Support Germline Genome-wide Genotyping and Sequencing of Existing Samples from Minority Racial/Ethnic Populations and Sharing of Associated Epidemiologic Data
  (NOT-CA-22-064)
  National Cancer Institute
  National Institute of Environmental Health Sciences

• Notice of NCI Participation in RFA-MD-22-008, Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
  (NOT-CA-22-066)
  National Cancer Institute

• Notice of Participation of Additional NIH Institutes and Centers in PAR-20-153: Science Education Partnership Awards (SEPA) (R25-Clinical Trial Not Allowed)
  (NOT-HG-22-006)
  National Human Genome Research Institute
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Office of Research on Women's Health

• Request for Information (RFI): Inviting Input on NIDAs Racial Equity Initiative Action Plan
  (NOT-DA-22-052)
  National Institute on Drug Abuse

Notice of Changes to Funding Opportunities

• Notice of Change to Update Other Clinical Trial-related Attachments in PAR-21-241 NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
  (NOT-AT-22-017)
  National Center for Complementary and Integrative Health

• Notice of Termination of RFA-DA-22-033, "Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed)"
  (NOT-DA-22-059)
  National Institute on Drug Abuse

• Notice of Change to Assistance Listing Number(s) for PA-21-151 "NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)"
  (NOT-ES-22-008)
  National Institute of Environmental Health Sciences

• Notice of NICHD Participation in PAR-22-000 "Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)"
  (NOT-HD-22-012)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

• Notice of Application Submission and Due Date Changes for RFA-HL-23-010, "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)"
  (NOT-HL-22-015)
  National Heart, Lung, and Blood Institute

• Notice of Application Due Date Changes for RFA-HL-23-011,"Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)"
  (NOT-HL-22-016)
  National Heart, Lung, and Blood Institute

• Notice of Application Due Date Changes for RFA-HL-23-012, "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)"
  (NOT-HL-22-017)
  National Heart, Lung, and Blood Institute

• Application Due Date Changes for RFA-HL-23-013, "Catalyze: Product Definition Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)"
  (NOT-HL-22-018)
  National Heart, Lung, and Blood Institute

• Application Due Date Changes for RFA-HL-23-014, "Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33)"
  (NOT-HL-22-019)
  National Heart, Lung, and Blood Institute

• Notice to Rescind NOT-NS-22-053 "Notice of Special Interest (NOSI): Pain-Focused Administrative Supplements for NINDS Grants that are Not Focused on Pain Research"
  (NOT-NS-22-092)
  National Institute of Neurological Disorders and Stroke

• Notice of Change in Eligibility to PAR-21-293 Clinical and Translational Science Award (UM1 Clinical Trial Optional)
  (NOT-TR-22-024)
  National Center for Advancing Translational Sciences

• Notice of Change in Award Information to PAR-21-293 Clinical and Translational Science Award (UM1 Clinical Trial Optional)
  (NOT-TR-22-025)
  National Center for Advancing Translational Sciences

• Notice of Change in Funding Opportunity Description and Application and Submission Information to PAR-21-293 Clinical and Translational Science Award (UM1 Clinical Trial Optional)
  (NOT-TR-22-026)
  National Center for Advancing Translational Sciences

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed)
  (NOT-DK-22-018)
  National Institute of Diabetes and Digestive and Kidney Diseases

• Notice of Intent to Publish a Funding Opportunity Announcement for Reproductive Scientist Development Program (RSDP) (K12 Clinical Trial Not Allowed)
  (NOT-HD-22-006)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

• Notice of Intent to Publish a Funding Opportunity Announcement for Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early Stage Development (UG3/UH3 Clinical Trial Not Allowed)
  (NOT-NS-22-086)
  National Institute of Neurological Disorders and Stroke
  National Eye Institute
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences

• Notice of Intent to Publish a Funding Opportunity Announcement for Impact of the Microbiome Gut-Brain Axis on ADRD (R01 Clinical Trial Not Allowed)
  (NOT-NS-22-088)
  National Institute of Neurological Disorders and Stroke

Notices of Special Interest

• Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Stimulate or Strengthen Global Cancer Health Disparities Research
  (NOT-CA-22-057)
  National Cancer Institute

• Notice of Special Interest (NOSI): Technological Innovations for Advancing Clinical SPECT Imaging
  (NOT-EB-22-006)
  National Institute of Biomedical Imaging and Bioengineering

• Notice of Special Interest (NOSI): Research using implementation science to support the delivery of evidence-based practices in community-based mental or general medical healthcare settings
  (NOT-MH-22-170)
  National Institute of Mental Health
  National Institute on Drug Abuse

• Notice of Special Interest(NOSI): Recruitment Innovation Center (RIC) Topic Area for Limited Competition: Clinical and Translational Science Award Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Optional)
  (NOT-TR-22-020)
  National Center for Advancing Translational Sciences

• Notice of Special Interest (NOSI) Trial Innovation Center (TIC) Topic Area for Limited Competition: Clinical and Translational Science Award (CTSA) Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Optional)
  (NOT-TR-22-021)
  National Center for Advancing Translational Sciences

Funding Opportunities

• Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
  (PAR-22-076)
  National Institute of Neurological Disorders and Stroke
   
• Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
  (PAR-22-126)
  National Institute of General Medical Sciences
  National Cancer Institute
  National Institute on Aging
   
• Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
  (PAR-22-127)
  National Institute of General Medical Sciences
  National Cancer Institute
  National Institute on Aging
   
• Patient Derived Xenograft (PDX) Development and Trial Centers (PDTCs) Network (U54 Clinical Trial Not Allowed)
  (RFA-CA-22-012)
  National Cancer Institute
   
• PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24 Clinical Trial Not Allowed)
  (RFA-CA-22-013)
  National Cancer Institute
   
• Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)
  (RFA-CA-22-017)
  National Cancer Institute
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Drug Abuse
   
• Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
  (RFA-CA-22-021)
  National Cancer Institute
   
• Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
  (RFA-CA-22-022)
  National Cancer Institute
   
• Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
  (RFA-CA-22-023)
  National Cancer Institute
   
• Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
  (RFA-CA-22-024)
  National Cancer Institute
   
• Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
  (RFA-DA-23-014)
  National Institute on Drug Abuse
   
• Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
  (RFA-MD-22-008)
  National Institute on Minority Health and Health Disparities
  National Cancer Institute
   
• Understanding Suicide Risk and Protective Factors among Black Youth (R01 Clinical Trial Not Allowed)
  (RFA-MH-22-140)
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  Office of Behavioral and Social Sciences Research
   
• Understanding Suicide Risk and Protective Factors among Black Youth (R21 Clinical Trial Not Allowed)
  (RFA-MH-22-141)
  National Institute of Mental Health
   
• BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)
  (RFA-MH-22-220)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
   

Members of the University of Iowa community may direct questions to the UI Division of Sponsored Programs at dsp@uiowa.edu(link sends e-mail)  or 335-2123, or email Ann Ricketts at ann-ricketts@uiowa.edu(link sends e-mail) or Lynn Hudachek at lynn-hudachek@uiowa.edu(link sends e-mail).